<p>/PRNewswire/ -- Cellipont Bioservices，一家领先的细胞治疗合同开发与制造组织（CDMO），今天宣布与 BobcatBio 达成战略合作，BobcatBio 是一家临床阶段的生物技术公司，正在开创 RB-1355 的开发，这是一种首创的细胞治疗，利用患者的巨噬细胞的多功能性和强大能力，诱导强有力的、针对性的肿瘤杀伤免疫反应，同时大幅减少或消除对传统癌症治疗方法（如化疗、高剂量放疗和手术）的依赖，从而改善患者的治疗效果和生活质量。这一突破性方法具有变革潜力，有望重新定义癌症治疗，成为广泛适用于各种实体肿瘤和淋巴瘤的首选疗法。早期临床发现显示，在复发或难治性非霍奇金淋巴瘤患者中，RB-1355 耐受性良好，并显示出令人鼓舞的早期活性迹象。最近的临床数据还表明，该疗法可以有效地在不进行淋巴耗竭化疗的情况下施用，并且可以通过冷冻保存从单次血浆分离中多次给药。</p>
<p>根据协议，Cellipont Bioservices 将进行 RB-1355 的第一阶段细胞产品制造，以支持 BobcatBio 正在进行的实体肿瘤和淋巴瘤临床试验。</p>
<p>&#34;在 Cellipont，我们致力于支持那些推动细胞治疗为患者带来新可能性的创新者，&#34; Cellipont Bioservices 首席执行官 Darren Head 表示。&#34;BobcatBio 的工作反映了这一领域所需的大胆科学，我们很自豪能够支持这一项目的推进，该项目有潜力为实体肿瘤开辟新的可能性。这样的合作不仅仅是制造，更是帮助将有前景的疗法带给那些期待更好选择的患者和家庭。&#34;</p>
<p>&#34;BobcatBio 正在推进一种高度差异化的细胞治疗方法，我们很高兴能与 Cellipont 合作，继续推动这一项目向前发展，&#34; BobcatBio 首席执行官 Stephen Rocamboli 表示。&#34;在我们努力将基于巨噬细胞的疗法带给患者的过程中，拥有一个理解细胞治疗开发复杂性和提供新治疗选择紧迫性的制造合作伙伴至关重要。Cellipont 具备推进 BobcatBio 创新细胞治疗所需的技术专长、质量关注、运营严谨性和可扩展基础设施。&#34;</p>
<p><strong>关于 Cellipont Bioservices</strong> Cellipont Bioservices 是一家顶级的合同开发与制造组织（CDMO），专注于细胞治疗的推进。Cellipont 拥有一支行业领先的专家团队，处于细胞治疗开发和制造的前沿，提供从工艺开发、分析服务到大规模商业制造的全面解决方案。我们专门建造的设施，加上我们尖端的技术和对质量的承诺，使我们能够支持客户向全球患者提供改变生命的细胞治疗。Cellipont Bioservices 致力于在我们运营的各个方面追求卓越，确保我们不仅满足而且超越客户和我们服务的社区的期望。欲了解更多信息，请访问 www.cellipont.com 并在 LinkedIn 上关注我们。</p>
<p>来源：Cellipont Bioservices</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMzE3Jk5ld3NJdGVtSWQ9REExMTMzMiZUcmFuc21pc3Npb25fSWQ9MjAyNjAzMTcxMDA4UFJfTkVXU19VU1BSX19fX19EQTExMzMy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMzE3Jk5ld3NJdGVtSWQ9REExMTMzMiZUcmFuc21pc3Npb25fSWQ9MjAyNjAzMTcxMDA4UFJfTkVXU19VU1BSX19fX19EQTExMzMy"/></p>

医疗业 ETF - SPDR

蓝鸟生物

医药突破 ETF - ALPS

<p>Cellipont Bioservices 宣布与 BobcatBio 达成战略合作，以推进针对实体肿瘤的巨噬细胞疗法。此次合作旨在支持 RB-1355 的生产，这是一种新型细胞疗法，利用患者的巨噬细胞增强对肿瘤的免疫反应，同时减少对传统癌症治疗的依赖。早期临床结果显示，RB-1355 耐受性良好且有效，无需淋巴耗竭化疗。此次合作强调了为有需要的患者提供创新疗法的承诺</p>

<p>, /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced a strategic collaboration with BobcatBio, a clinical-stage biotechnology company that is pioneering the development of RB-1355, a first of its kind cellular therapy that leverages the versatility and power of a patient's macrophages to elicit a robust, targeted tumoricidal immune response while substantially reducing or eliminating the reliance on traditional cancer treatments such as chemotherapy, high-dose radiation and surgery, thereby improving patient outcomes and quality of life. This breakthrough approach holds transformative potential to redefine cancer treatment, offering the prospect of becoming a preferred therapy across a wide spectrum of solid tumors and lymphomas. Early clinical findings in relapsed or refractory non-Hodgkin lymphoma indicate that RB-1355 is well tolerated with encouraging early signs of activity. Recent clinical data also demonstrated that the therapy can be effectively administered without lymphodepleting chemotherapy and in multiple doses from a single apheresis through cryopreservation.</p>
<div class="lb-trans"><p>/PRNewswire/ -- Cellipont Bioservices，一家领先的细胞治疗合同开发与制造组织（CDMO），今天宣布与 BobcatBio 达成战略合作，BobcatBio 是一家临床阶段的生物技术公司，正在开创 RB-1355 的开发，这是一种首创的细胞治疗，利用患者的巨噬细胞的多功能性和强大能力，诱导强有力的、针对性的肿瘤杀伤免疫反应，同时大幅减少或消除对传统癌症治疗方法（如化疗、高剂量放疗和手术）的依赖，从而改善患者的治疗效果和生活质量。这一突破性方法具有变革潜力，有望重新定义癌症治疗，成为广泛适用于各种实体肿瘤和淋巴瘤的首选疗法。早期临床发现显示，在复发或难治性非霍奇金淋巴瘤患者中，RB-1355 耐受性良好，并显示出令人鼓舞的早期活性迹象。最近的临床数据还表明，该疗法可以有效地在不进行淋巴耗竭化疗的情况下施用，并且可以通过冷冻保存从单次血浆分离中多次给药。</p>
</div><p>Under the agreement, Cellipont Bioservices will perform Phase I cell product manufacturing of RB-1355 in support of BobcatBio's ongoing solid tumor and lymphoma clinical trials.</p>
<div class="lb-trans"><p>根据协议，Cellipont Bioservices 将进行 RB-1355 的第一阶段细胞产品制造，以支持 BobcatBio 正在进行的实体肿瘤和淋巴瘤临床试验。</p>
</div><p>&#34;At Cellipont, we are committed to supporting innovators who are pushing the boundaries of what cell therapy can do for patients,&#34; said Darren Head, CEO, Cellipont Bioservices. &#34;BobcatBio's work reflects the kind of bold science this field needs, and we are proud to support the advancement of a program with the potential to open new possibilities in solid tumors. Collaborations like this are about more than manufacturing. They are about helping bring promising therapies closer to patients and families who are waiting for better options.&#34;</p>
<div class="lb-trans"><p>&#34;在 Cellipont，我们致力于支持那些推动细胞治疗为患者带来新可能性的创新者，&#34; Cellipont Bioservices 首席执行官 Darren Head 表示。&#34;BobcatBio 的工作反映了这一领域所需的大胆科学，我们很自豪能够支持这一项目的推进，该项目有潜力为实体肿瘤开辟新的可能性。这样的合作不仅仅是制造，更是帮助将有前景的疗法带给那些期待更好选择的患者和家庭。&#34;</p>
</div><p>&#34;BobcatBio is advancing a highly differentiated approach to cell therapy, and we are pleased to partner with Cellipont as we continue to move this program forward,&#34; said Stephen Rocamboli, CEO, BobcatBio &#34;As we work to bring our macrophage-based therapy closer to patients, it is critical to have a manufacturing partner that understands both the complexity of cell therapy development and the urgency of delivering new treatment options. Cellipont brings the technical expertise, quality focus, operational rigor, and scalable infrastructure needed to advance BobcatBio's innovative cellular therapy.&#34;</p>
<div class="lb-trans"><p>&#34;BobcatBio 正在推进一种高度差异化的细胞治疗方法，我们很高兴能与 Cellipont 合作，继续推动这一项目向前发展，&#34; BobcatBio 首席执行官 Stephen Rocamboli 表示。&#34;在我们努力将基于巨噬细胞的疗法带给患者的过程中，拥有一个理解细胞治疗开发复杂性和提供新治疗选择紧迫性的制造合作伙伴至关重要。Cellipont 具备推进 BobcatBio 创新细胞治疗所需的技术专长、质量关注、运营严谨性和可扩展基础设施。&#34;</p>
</div><p><strong>About Cellipont Bioservices</strong> Cellipont Bioservices is a premier Contract Development and Manufacturing Organization (CDMO) specializing in the advancement of cell therapies. With a team of industry-leading experts, Cellipont is at the forefront of cell therapy development and manufacturing, offering comprehensive solutions from process development, analytical services, to large-scale commercial manufacturing. Our purpose-built facility, combined with our cutting-edge technology and commitment to quality enable us to support our clients in delivering life-changing cell therapies to patients worldwide. Cellipont Bioservices is dedicated to excellence in all aspects of our operations, ensuring that we not only meet but exceed the expectations of our clients and the communities we serve. To learn more, visit www.cellipont.com and follow us on LinkedIn.</p>
<div class="lb-trans"><p><strong>关于 Cellipont Bioservices</strong> Cellipont Bioservices 是一家顶级的合同开发与制造组织（CDMO），专注于细胞治疗的推进。Cellipont 拥有一支行业领先的专家团队，处于细胞治疗开发和制造的前沿，提供从工艺开发、分析服务到大规模商业制造的全面解决方案。我们专门建造的设施，加上我们尖端的技术和对质量的承诺，使我们能够支持客户向全球患者提供改变生命的细胞治疗。Cellipont Bioservices 致力于在我们运营的各个方面追求卓越，确保我们不仅满足而且超越客户和我们服务的社区的期望。欲了解更多信息，请访问 www.cellipont.com 并在 LinkedIn 上关注我们。</p>
</div><p>SOURCE Cellipont Bioservices</p>
<div class="lb-trans"><p>来源：Cellipont Bioservices</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMzE3Jk5ld3NJdGVtSWQ9REExMTMzMiZUcmFuc21pc3Npb25fSWQ9MjAyNjAzMTcxMDA4UFJfTkVXU19VU1BSX19fX19EQTExMzMy" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=DA11332&amp;Transmission_Id=202603171008PR_NEWS_USPR_____DA11332&amp;DateId=20260317"/></p>

10:08 ETCellipont Bioservices and BobcatBio Announce Strategic Collaboration to Advance Macrophage Cell Therapy for Solid Tumors

prnewswire

2 倍做多纳斯达克生物技术 ETF - ProShares

美国制药 ETF - iShares

医疗业 ETF - Vanguard

标普生物技术 3 倍做多 - Direxion

Propanc Biopharma

Invesco Nasdaq Biotechnology ETF

纽交所高增长板生物技术指数 ETF - First Trust

生物科技 ETF - VanEck Vectors

标普生物技术 ETF - SPDR

Avid Bioservices

Mustang Bio

基因改革 ETF - ARK

纳斯达克生物科技指数 ETF - iShares Nasdaq

Crescent Biopharma

动态生物技术与基因组 ETF - Invesco

标普全球医疗股指数 ETF - iShares

Cellipont Bioservices 和 BobcatBio 宣布战略合作，以推进实体瘤的巨噬细胞疗法